Enterprise Value
-49.41M
Cash
112M
Avg Qtr Burn
-14.17M
Short % of Float
3.57%
Insider Ownership
0.54%
Institutional Own.
39.34%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Voruciclib (CDK Inhibitor) Details B-cell malignancies, Acute myeloid leukemia, Cancer | Phase 1b Data readout | |
ME-344 (Mitochondrial Inhibitor) Details Cancer, Solid tumor/s | Phase 1b Initiation | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details Follicular lymphoma | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued |